The Vanguard Group has filed an amended Schedule 13G with the Securities and Exchange Commission on November 12, 2024, indicating a 9.63% ownership stake in Novavax Inc. This filing, which reflects the state of ownership as of September 30, 2024, reports that The Vanguard Group has beneficial ownership of 15,430,034 shares of Novavax's common stock. The group has shared voting power over 224,741 shares and sole dispositive power over 15,072,218 shares, with an additional shared dispositive power over 357,816 shares. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Novavax and were not held in connection with any transaction having that purpose or effect.

The Vanguard Group has filed an amended Schedule 13G with the Securities and Exchange Commission on November 12, 2024, indicating a 9.63% ownership stake in Novavax Inc. This filing, which reflects the state of ownership as of September 30, 2024, reports that The Vanguard Group has beneficial ownership of 15,430,034 shares of Novavax's common stock. The group has shared voting power over 224,741 shares and sole dispositive power over 15,072,218 shares, with an additional shared dispositive power over 357,816 shares. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Novavax and were not held in connection with any transaction having that purpose or effect.